Superparamagnetic nanoparticles as potential drug delivery systems for the treatment of Duchenne muscular dystrophy

被引:0
|
作者
Schumacher, Maria L. [1 ]
Britos, Tatiane N. [1 ]
Fonseca, Fernando L. A. [2 ]
Ferreira, Fabio F. [3 ,4 ]
Feder, David [2 ]
Fratini, Paula [2 ]
Petri, Giuliana [2 ]
Haddad, Paula S. [1 ]
机构
[1] Fed Univ Sao Paulo UNIFESP, Dept Chem, Diadema, SP, Brazil
[2] Fac Med ABC FMABC, Santo Andre, SP, Brazil
[3] Fed Univ ABC UFABC, Ctr Nat & Human Sci CCNH, Santo Andre, SP, Brazil
[4] Fed Univ ABC UFABC, Nanomed Res Unit NANOMED, Santo Andre, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
IRON-OXIDE NANOPARTICLES; CYSTEINE; MAGNETITE; HEMATITE; MRI;
D O I
10.1039/d4nr03407d
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This study aims to use superparamagnetic iron oxide nanoparticles (SPIONs), specifically magnetite (Fe3O4), to deliver deflazacort (DFZ) and ibuprofen (IBU) to Duchenne muscular dystrophy-affected (DMD) mouse muscles using an external magnetic field. The SPIONs are synthesized by the co-precipitation method, and their surfaces are functionalized with l-cysteine to anchor the drugs, considering that the cysteine on the surface of the SPIONs in the solid state dimerizes to form the cystine molecule, creating the Fe3O4-(Cys)2-DFZ and Fe3O4-(Cys)2-IBU systems for in vivo tests. The Fe3O4 nanoparticles (NPs) were characterized by Fourier transform infrared spectroscopy (FTIR), Raman spectroscopy, powder X-ray diffraction (PXRD), transmission electron microscopy (TEM), dynamic light scattering (DLS), and magnetic measurements. The results show that the SPIONs have an average crystallite size of about 8 nm in the solid state and a hydrodynamic size of about 120 nm, which is suitable for biological applications in aqueous dispersion. The nanoparticles exhibit superparamagnetic behavior at room temperature and spherical-close morphology. In addition, vibrational modes characteristic of the functional groups of the molecules anchored to the surface of the SPIONs are identified. Data from blood tests of mdx mice after seven consecutive days of treatment with nanoparticles confirm the non-toxic nature of the system and show an improvement in DMD, with normal levels of liver and kidney enzymes and a decrease in creatine kinase protein.
引用
收藏
页码:3752 / 3767
页数:16
相关论文
共 50 条
  • [1] Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
    Namgoong, John Hyun
    Bertoni, Carmen
    DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2016, 6 : 37 - 48
  • [2] The Potential of Exon Skipping for Treatment for Duchenne Muscular Dystrophy
    Partridge, Terence
    JOURNAL OF CHILD NEUROLOGY, 2010, 25 (09) : 1165 - 1170
  • [3] The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy
    Guiraud, Simon
    Roblin, David
    Kay, Davies E.
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (03): : 179 - 192
  • [4] Calpain inhibitors, a potential treatment for Duchenne muscular dystrophy
    Lescop, C
    Siendt, H
    Bolliger, R
    Henneböhle, M
    Herzner, H
    Weyermann, P
    von Sprecher, A
    Foster, M
    Courdier-Fruh, I
    Erb, M
    Briguet, A
    Magyar, JP
    Proceedings of the Joint Meeting on Medicinal Chemistry, 2005, : 95 - 98
  • [5] THE POTENTIAL OF EXOSOMES FOR THE DIAGNOSIS AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    Galkin, I. I.
    Egorova, T., V
    BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2019, (04): : 5 - 8
  • [6] In vitro profiling of calpain inhibitors as potential drug candidates for the treatment of Duchenne muscular dystrophy
    Briguet, A
    Foster, M
    Courdier-Fruh, I
    Meier, T
    Magyar, JP
    NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 613 - 613
  • [7] Green tea polyphenols as potential treatment of Duchenne muscular dystrophy
    Ruegg, U. T.
    Dorchies, O. M.
    Reutenauer, J.
    Vuadens, O.
    Roulet, E.
    NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 813 - 814
  • [8] Targeting mRNA Splicing as a Potential Treatment for Duchenne Muscular Dystrophy
    Kole, Ryszard
    Leppert, Brian J.
    DISCOVERY MEDICINE, 2012, 14 (74) : 59 - 69
  • [9] Drug evaluation: PTC-124 - a potential treatment for cystic fibrosis and Duchenne muscular dystrophy
    Hamed, Sherifa A.
    IDRUGS, 2006, 9 (11) : 783 - 789
  • [10] Update on the Treatment of Duchenne Muscular Dystrophy
    Rodino-Klapac, Louise R.
    Mendell, Jerry R.
    Sahenk, Zarife
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2013, 13 (03)